Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen-A novel biomarker of atherosclerotic plaque remodeling

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 900-906

  Barascuk, Natasha ^a,d   Vassiliadis, Efstathios ^a   Larsen, Lise ^a   Wang, Jianxia ^b   Zheng, Qinlong ^b   Xing, Rui ^b   Cao, Yu ^b   Crespo, Christine ^c   Lapret, Isabelle ^c   Sabatini, Massimo ^c   Villeneuve, Nicole ^c   Vilaine, Jean Paul ^c   Rasmussen, Lars Melholt ^d   Register, Thomas C ^e   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Nordic Bioscience Beijing   (China)

^c INSTITUT DE RECHERCHES SERVIER   (France)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e WAKE FOREST UNIVERSITY   (United States)

Author keywords

Apolipoprotein knockout mouse; Atherosclerosis; Collagen; Extracellular matrix remodeling; Matrix metalloproteinase

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN TYPE 3; GELATINASE B; MONOCLONAL ANTIBODY;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROTIC PLAQUE; COLLAGEN DEGRADATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; LIMIT OF DETECTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINE LEVEL; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CHOLESTEROL; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MASS SPECTROMETRY; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PLAQUE, ATHEROSCLEROTIC; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SUBSTRATE SPECIFICITY; TRIGLYCERIDES;

EID: 79958847622     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.04.004     Document Type: Article

References (28)

1. Barnes M.J., Farndale R.W. Collagens and atherosclerosis. Exp Gerontol 1999 July, 34(4):513-525.
2. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., Fallon J.T. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994 August, 90(2):775-778.
3. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005 April 6, 293(13):1609-1616.
4. Bonnet J., Garderes P.E., Aumailley M., et al. Serum type III procollagen peptide levels in coronary artery disease (a marker of atherosclerosis). Eur J Clin Invest 1988 February, 18(1):18-21.
5. Aikawa M., Rabkin E., Voglic S.J., et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res 1998 November 16, 83(10):1015-1026.
6. Newby A.C. Molecular and cell biology of native coronary and vein-graft atherosclerosis: regulation of plaque stability and vessel-wall remodelling by growth factors and cell-extracellular matrix interactions. Coron Artery Dis 1997 March, 8(3-4):213-224.
7. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005 January, 85(1):1-31.
8. Garnero P., Ferreras M., Karsdal M.A., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003 May, 18(5):859-867.
9. Schaller S., Henriksen K., Sveigaard C., et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004 July, 19(7):1144-1153.
10. Sondergaard B.C., Henriksen K., Wulf H., et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 2006 August, 14(8):738-748.
11. Gefter M.L., Margulies D.H., Scharff M.D. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 1977 March, 3(2):231-236.
12. Fishbein M.C., Siegel R.J. How big are coronary atherosclerotic plaques that rupture?. Circulation 1996 November 15, 94(10):2662-2666.
13. Pasterkamp G., de Kleijn D.P., Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res 2000 March, 45(4):843-852.
14. Schoenhagen P., Ziada K.M., Kapadia S.R., Crowe T.D., Nissen S.E., Tuzcu E.M. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000 February 15, 101(6):598-603.
15. Ivan E., Khatri J.J., Johnson C., et al. Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: the murine model of macrophage-rich carotid artery lesions. Circulation 2002 June 4, 105(22):2686-2691.
16. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002 February 22, 90(3):251-262.
17. Galis Z.S., Sukhova G.K., Kranzhofer R., Clark S., Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995 January 17, 92(2):402-406.
18. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994 December, 94(6):2493-2503.
19. Shah P.K., Falk E., Badimon J.J., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995 September 15, 92(6):1565-1569.
20. Pasterkamp G., Schoneveld A.H., van der Wal A.C., et al. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol 1998 September, 32(3):655-662.
21. Karsdal M.A., Henriksen K., Leeming D.J., et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009 May, 14(3):181-202.
22. Bagger Y.Z., Tanko L.B., Alexandersen P., et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005 September, 37(3):425-430.
23. Meulenbelt I., Kloppenburg M., Kroon H.M., et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 2006 March, 65(3):360-365.
24. Bauer D.C., Hunter D.J., Abramson S.B., et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006 August, 14(8):723-727.
25. Desai A., Zhao Y., Warren J.S. Development of atherosclerosis in Balb/c apolipoprotein E-deficient mice. Cardiovasc Pathol 2008 July, 17(4):233-240.
26. Garcia-Touchard A., Henry T.D., Sangiorgi G., et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 2005 June, 25(6):1119-1127.
27. Botney M.D., Kaiser L.R., Cooper J.D., et al. Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. Am J Pathol 1992 February, 140(2):357-364.
28. Katsuda S., Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003, 10(5):267-274.